Close Menu

NEW YORK (GenomeWeb News) – Bio-Rad Laboratories has purchased next-generation sequencing technology firm GnuBio for an undisclosed price in order to give it capabilities in the NGS space, especially for clinical applications, Bio-Rad said this week.

Cambridge, Mass.-based GnuBio is developing a droplet-based sequencing platform that uses "picoinjector" technology developed in co-founder David Weitz’s physics laboratory at Harvard University.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.

Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.

The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.

In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.

Jun
11
Sponsored by
Roche

This webinar will overview the potential for liquid biopsy approaches to monitor therapy resistance in lung cancer.

Jun
19
Sponsored by
Roche

This webinar will discuss cell-free DNA prenatal screening in the era of genome-wide sequencing and factors influencing the clinical utility of expanded noninvasive prenatal testing (NIPT) menus.